(MedPage Today) — Exposure to proton pump inhibitors (PPIs) was associated with worse progression-free survival (PFS) and overall survival (OS) in patients with locally advanced non-small cell lung cancer (NSCLC) who were treated with durvalumab…
Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/122068
Author :
Publish date : 2026-07-06 20:38:00
Copyright for syndicated content belongs to the linked Source.













